An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic triple-negative breast cancer (mTNBC).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Steven O'Day, Virginia F. Borges, Bartosz Chmielowski, Ruta D. Rao, Maysa M. Abu-Khalaf, Alison Stopeck, Petros Nikolinakos, Melinda L. Telli, Bin Xie, Montaser F. Shaheen, Paulette Mattson, Michele Anne Gargano, Joanna Cox, Vassiliki Karantza, Michael Jon Chisamore, Bruno Osterwalder, Nandita Bose, Mark T. Uhlik, Jeremy Graff
Institutions: University of Colorado Cancer Center, University of California, Los Angeles, Rush University Medical Center, Sidney Kimmel Cancer Center, University Cancer and Blood Center, Stanford Medicine, Stanford University, University of Arizona Cancer Center, Biothera (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Merck KGaA, Darmstadt (Germany)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947161726